Biogen stumbles in crucial ALS study
Even though Biogen's drug candidate tofersen has not achieved its primary endpoint goal in an important phase III study of a particular sub-type of ALS, there are enough positive signs for the company to keep investigating next steps for the drug.
by christopher due karlsson, translated by catherine brett
US-based biotech company Biogen has not managed to attain its primary endpoint goal in a crucial phase III study of its canditate tofersen, also called BIIB067, as a treatment for a specific type of ALS, SOD1-ALS, the firm reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
